Tenaya Therapeutics (TNYA)

• Market cap: $103M
• 1 day: -7.14%
• 5 days: -16.13%
• 1 month: -18.24%
• 3 months: -32.29%
• 6 months: -64.58%
• Year to date: -8.45%
• 1 year: -72.57%
• 5 years: -91.53%
• 10 years: -91.53%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.

Employees: 140

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2,000% more call options, than puts

Call options by funds: $21K | Put options by funds: $1K

89% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 19

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

0.39% more ownership

Funds ownership: 72.69% [Q2] → 73.08% (+0.39%) [Q3]

0% more funds holding

Funds holding: 95 [Q2] → 95 (+0) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]

37% less capital invested

Capital invested by funds: $177M [Q2] → $111M (-$65.7M) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $18 1,285% upside
• Avg. target: $18 1,285% upside
• High target: $18 1,285% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 30% 1-year accuracy 118 / 399 met price target	1,285% upside $18	Buy Reiterated	14 Jan 2025
Chardan Capital Geulah Livshits 8% 1-year accuracy 4 / 49 met price target	1,285% upside $18	Buy Maintained	18 Dec 2024